Ginkgo Q2 revenue $81M (-44% YoY); Cell Engineering services up 72%; guides FY23 rev $245-260M

Ginkgo Bioworks Holdings, Inc.

2023-Q2 EPS reported -$0.20 revenue$161,270,000

Q2 total revenue $81M, down 44% YoY as Biosecurity K-12 testing wound down.
Cell Engineering services revenue $44M, up 72% YoY; total Cell Engineering $45M.
Biosecurity revenue $35M (49% gross margin); expanding internationally.
Adjusted EBITDA loss $(75)M; operating loss $(184)M including $62M stock comp.
FY23 guidance: total rev $245-260M, Cell Eng rev revised to $145-160M, Bio at least $100M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ginkgo Bioworks Holdings, Inc. reported second quarter ended June 30, 2023 results: revenue $81 million. Guidance reaffirmed.

Period: second quarter ended June 30, 2023
Revenue: $81 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Second quarter 2023 Total revenue of $81 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040716

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.